US · MREO
Mereo BioPharma Group plc
- Sector
- Healthcare · Biotechnology
- Headquarters
- London W1G 0QF
- Website
- mereobiopharma.com
Price · as of 2024-12-31
$0.26
Market cap 59.17M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $33.26 | +12,692.31% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $1.89 | ||||
| 2020 | $4.08 | ||||
| 2021 | $1.35 | $1.15 | $1.75 | ||
| 2022 | $0.78 | $28.84 | |||
| 2023 | $3.58 | $0.23 | $0.00 | ||
| 2024 | $2.49 | $33.26 |
AI valuation
Our deep-learning model estimates Mereo BioPharma Group plc's (MREO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $33.26
- Current price
- $0.26
- AI upside
- +12,692.31%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MREO | Mereo BioPharma Group plc | $0.26 | 59.17M | +12,692% | — | — | — | -8.52 | 6.04 | — | -7.48 | — | 6.11 | 0.00% | — | — | -77.58% | 2839.57% | -60.54% | 0.11 | -34.56 | 5.40 | 5.28 | 1.55 | -9997.00% | -10000.00% | 5560.00% | -9.10% | -2.37 | 2010.37% | 0.00% | 0.00% | 3.23% | -6.44 | -9.09 | — | 4.76 |
| ACIU | AC Immune S.A. | $2.93 | 294.76M | +1,817% | -50% | — | — | -3.77 | 1.71 | 7.03 | -0.66 | — | 3.10 | -129.12% | -191.80% | -186.44% | -37.31% | -787.64% | -24.61% | 0.05 | -393.82 | 1.71 | 1.65 | 0.63 | -2031.00% | 8451.00% | -20663.00% | 34.00% | 0.65 | 981.44% | 0.00% | 0.00% | 0.00% | -0.61 | 0.49 | 1.17 | -1.52 |
| ALDX | Aldeyra Therapeutics, Inc… | $5.46 | 328.49M | — | — | — | — | 0.00 | 0.00 | — | 1.55 | — | 0.00 | 0.00% | — | — | -152.98% | 0.00% | -93.94% | 0.35 | -18.51 | 2.58 | 2.52 | 1.55 | -4043.00% | — | 7717335287.00% | -9879606.86% | -1.20 | 649.97% | 0.00% | 0.00% | 16150447.97% | 1545737.39 | 1.63 | — | -8.67 |
| CADL | Candel Therapeutics, Inc. | $5.25 | 288.22M | — | — | — | — | -4.74 | 3.94 | — | -3.31 | -14.45 | 3.94 | 0.00% | — | — | -139.56% | 293.22% | -74.53% | 0.20 | -15.97 | 2.77 | 2.74 | 1.71 | 3282.00% | — | -2208.00% | -10.33% | -0.72 | 237.58% | 0.00% | 0.00% | 29.25% | -5.17 | -6.38 | — | 1.07 |
| CAPR | Capricor Therapeutics, In… | $27.93 | 1.28B | -15% | -76% | — | -88% | -11.15 | 3.10 | 20.26 | -7.32 | -28.92 | 3.10 | -124.37% | -191.13% | -181.71% | -48.16% | 442.17% | -35.31% | 0.01 | — | 7.77 | 7.70 | 0.24 | 3855.00% | -1155.00% | 5025.00% | -9.21% | -1.90 | 431.47% | 0.00% | 0.00% | 0.00% | -7.07 | -7.25 | 13.52 | 9.49 |
| CTNM | Contineum Therapeutics, I… | $15.34 | 560.36M | +1,304% | — | — | — | -3.10 | 0.66 | — | 1.61 | — | 0.66 | 0.00% | — | — | -64.95% | 27584.82% | -24.62% | 0.03 | — | 20.69 | 20.53 | 0.37 | -34222.00% | -10000.00% | -27618.00% | -25.46% | -3.29 | 18080.76% | 0.00% | 0.00% | 147.57% | 1.33 | 2.02 | — | 4.86 |
| IMMP | Immutep Limited | $2.80 | 412.14M | +523% | -76% | — | — | -5.97 | 2.55 | 72.72 | -3.80 | -35.82 | 2.69 | -1117.55% | -2506.49% | -1218.02% | -36.88% | -1019.26% | -34.27% | 0.01 | — | 11.69 | 10.17 | 1.05 | 1667.00% | 3128.00% | 7368.00% | -16.93% | -4.86 | -500.64% | 0.00% | 0.00% | 0.00% | -1.89 | -3.84 | 47.33 | 10.94 |
| KYTX | Kyverna Therapeutics, Inc… | $8.21 | 359.53M | — | — | — | — | -0.78 | 0.37 | — | 1.42 | 0.00 | 0.37 | 0.00% | — | — | -80.74% | 2732.66% | -67.12% | 0.03 | -1004.25 | 8.61 | 8.47 | 0.71 | 332990000.00% | — | 11960.00% | -116.84% | -3.38 | 2231.58% | 0.00% | 0.00% | 63.02% | 1.25 | 1.53 | — | -0.17 |
| LXEO | Lexeo Therapeutics, Inc. … | $7.18 | 524.05M | — | — | — | — | -0.87 | 0.73 | — | 0.27 | -3.62 | 0.73 | 0.00% | — | — | -85.37% | -2362.17% | -68.58% | 0.08 | -927.77 | 5.52 | 5.32 | 0.26 | 2410.00% | — | 3683.00% | -95.11% | -3.55 | -1823.16% | 0.00% | 0.00% | 0.02% | 0.24 | 0.32 | — | -2.49 |
| PRQR | ProQR Therapeutics N.V. | $1.59 | 167.5M | +4,852% | +2,420% | — | — | -4.80 | 1.50 | 7.05 | -0.05 | — | 1.50 | 100.00% | -161.18% | -146.86% | -41.35% | 56.30% | -17.34% | 0.19 | -28.29 | 3.95 | 3.84 | 5.48 | -286.00% | 19022.00% | -28740.00% | -28.37% | -0.94 | 70.36% | 0.00% | 0.00% | 16.97% | -0.04 | -0.03 | 0.06 | -2.22 |
| SLN | Silence Therapeutics plc | $5.44 | 256.95M | +597% | -16% | — | — | -2.07 | 0.56 | 1.73 | 1.48 | — | 0.60 | 72.70% | -146.38% | -104.74% | -46.39% | 212.32% | -22.47% | 0.00 | — | 11.14 | 10.36 | 2.47 | -3190.00% | 7047.00% | 7223.00% | -90.74% | -4.02 | 227.52% | 0.00% | 0.00% | 70.57% | 1.14 | 1.07 | -1.67 | -2.43 |
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
- CEO
- Denise Vera Scots-Knight
- Employees
- 36
- Beta
- 0.26
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.26) − 1 = — (DCF, example).